The case in front of me: ecnoglutide · a C4 column · survodutide.
I would like the axes of comparison first and the recommendation second.
I have tried the first option and it works; the question is whether the second is better rather than merely different.
Is there a defensible reason to prefer one, or is this a coin flip?
The relevant detail is that start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.
Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.
Specifically, mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.
The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsSpecifically, high-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."
Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.
The relevant detail is that trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.
Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.
I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.
Ask for the chromatogram and the system suitability data, not just the number.
Stated carefully, method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.
Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.
Put another way, the 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.
The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.
The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.
Put another way, the most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.
Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.
The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.
Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
edited 27 May 2024 by h_villanueva — tightened the wording; no substantive change
On the detail: system suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.
System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.
Ask for the chromatogram and the system suitability data, not just the number.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.